Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Measles
Research from Mayo Clinic reveals new findings on measles
November 12th, 2008
According to recent research published in the journal Molecular Therapy, "The majority of glioblastoma multiforme (GBM) tumors (80%) overexpress interleukin-13 receptor alpha 2 (IL-13R alpha 2), but there is no expression of IL-13R alpha 2 in normal brain. Vaccine strains of measles virus have significant antitumor activity against gliomas." "We tested the hypothesis that measles virus entry could be retargeted via the IL-13R alpha 2. MV-GFP-H-AA-IL-13 was generated from the Edmonston-NSe vaccine strain, by displaying human IL-13 at the C-terminus of the H protein, and introducing CD46 and signaling lymphocyte activation molecule (SLAM)-ablating mutations in H....
Source: Vaccine Weekly (2008-11-12)
|
